Renalytix AI enters new partnership in America's 'diabetes belt'
19th May 2021 10:06
(Sharecast News) - Renalytix AI announced a partnership with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine on Wednesday, to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations.
Read moreRenalytix AI wins 10-year US government contract
22nd Apr 2021 16:03
(Sharecast News) - Renalytix AI announced on Thursday that the United States government has granted it a 10-year 'Governmentwide Acquisition Contract' (GWAC) to provide 'KidneyIntelX' early-stage kidney disease bioprognostic testing services.
Read moreRenalytix AI upbeat on new study findings
20th Apr 2021 13:48
(Sharecast News) - Renalytix AI announced the findings of a new study in which the commercially-available 'KidneyIntelX' test accurately predicted the progression of diabetic kidney disease (DKD) in a multinational cohort from the CANagliflozin CardioVAScular Assessment Study (CANVAS), with early-stage DKD.
Read moreRenalytix AI enters option agreement with Joslin Diabetes Center
14th Apr 2021 09:02
(Sharecast News) - Renalytix AI has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on additional novel biomarkers in kidney disease, it announced on Wednesday, for development and deployment in the 'KidneyIntelX' in vitro prognostic platform.
Read moreRenalytix AI upbeat on KidneyIntelX study results
8th Apr 2021 08:20
(Sharecast News) - Renalytix AI announced findings presented in a late-breaking presentation at the National Kidney Foundation's 2021 Spring Clinical Meetings on Thursday, titled 'Clinical Utility of a New Prognostic Test to Predict the Risk of Kidney Function Decline in Diabetic Kidney Disease Patients'.
Read moreRenalytix AI upbeat on latest 'KidneyIntelX' study results
6th Apr 2021 11:08
(Sharecast News) - Renalytix AI reported on Tuesday that its 'KidneyIntelX' product more accurately predicted progressive kidney function decline and kidney failure in a multi-centre, diverse cohort of 1,146 type-2 diabetes patients with early-stage kidney disease, when compared to the current standard of care.
Read moreRenalytix AI confident despite delay to new US Medicare rule
15th Mar 2021 08:55
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix AI updated the market on the establishment of the 'Medicare Coverage of Innovative Technology' (MCIT) pathway on Monday, reporting a 60-day delay to its implementation.
Read moreRenalytix AI losses widen as it progresses development programme
2nd Mar 2021 10:39
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix AI recorded $0.4m (£0.29m) of pharmaceutical services revenue in its first half, it announced on Tuesday.
Read moreRenalytix AI enters partnership with Univeristy of Utah Health
24th Feb 2021 11:28
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix AI announced a partnership with the University of Utah on Wednesday, to improve kidney health and reduce the risk of kidney failure for large-scale populations in the earliest stages of kidney disease.
Read moreSunday share tips: N Brown, Foxtons
17th Jan 2021 19:56
(Sharecast News) - The Financial Mail on Sunday's Midas column touted a raft of shares which it expected would benefit from the fight against obesity as well as the associated, and sometimes fatal, health risks.
Read moreRenalytix AI enters chronic kidney disease partnership with DaVita
5th Jan 2021 09:31
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix AI announced on Tuesday that it was partnering with DaVita on a programme aimed at slowing disease progression and improving health outcomes for the 37 million adults in the United States with chronic kidney disease (CKD).
Read moreRenalytix AI commercially launches KidneyIntelX
18th Sep 2020 12:49
(Sharecast News) - Artificial intelligence kidney diagnostics technology company Renalytix AI announced the commercial launch of its 'KidneyIntelX' clinical test reporting platform within the Mount Sinai Health System in New York City on Friday.
Read moreRenalytix AI gets clinical laboratory permit in New York state
12th Jun 2020 12:33
(Sharecast News) - Artificial intelligence (AI) in vitro diagnostics company Renalytix AI has received a clinical laboratory permit from the New York State Department of Health (NYS DOH) to provide commercial testing of its 'KidneyIntelX' product.
Read moreRenalytix AI upbeat on latest 'KidneyIntelX' research
10th Jun 2020 09:26
(Sharecast News) - Artificial intelligence (AI)-focussed diagnostics company Renalytix AI revealed more details of results from a multi-centre clinical validation of 'KidneyIntelX' on Wednesday, which reportedly demonstrated that KidneyIntelX could identify patients at the highest risk of early-stage diabetic kidney disease, with more accuracy than existing care methods.
Read moreUS national pricing comes into effect for Renalytix AI
3rd Jan 2020 08:46
(Sharecast News) - Artificial intelligence-enabled kidney disease clinical diagnostics technology company Renalytix AI announced on Friday that the United States national price for its 'KidneyIntelX' product, set by the Centers for Medicare and Medicaid Services (CMS), became effective on 1 January.
Read more